NervGen’s lead drug candidate, NVG-291, has potential to treat nervous system damage, whether as a result of injury or disease. It is a first-in-class therapeutic administered by injection under the skin. NVG-291 is currently in a Phase 1 clinical trial in healthy volunteers to evaluate safety, tolerability and metabolism.
Nervous System Damage
When there is damage to the nervous system a scar forms. The scar forms in response to acute damage, such as spinal cord injury and traumatic brain injury, or in chronic diseases, such as Alzheimer’s and multiple sclerosis. Scars contain molecules called chondroitin sulfate proteoglycans (CSPGs), which initially help to contain damage, but in the long term interfere with repair of the nervous system. In animal studies, NVG-291-R promoted nervous system repair and enhanced recovery of functions such as walking, bladder control, vision, and memory.
NervGen’s lead drug candidate, NVG-291, has potential to treat nervous system damage, whether as a result of injury or disease. NVG-291, a first-in-class neuroreparative drug candidate, is currently in a Phase 1 clinical trial in healthy volunteers. After completing our Phase 1 clinical trial, we plan to study the effectiveness and safety of NVG-291 initially in people with Alzheimer’s, spinal cord injury and multiple sclerosis.
|Indication||Phase 1||Phase 1b/2 Initiation||Phase 1b/2 Readout||Estimated Cost|
|Alzheimer’s Disease||Q4 2022||2024||$20 M|
|Spinal Cord Injury||Q4 2022||2023||$10 M|
|Multiple Sclerosis||Q1 2023||2024||$20 M|
Read about NVG-291 and Alzheimer’s.
Spinal Cord Injury
Read about NVG-291 and spinal cord injury.
Read about NVG-291 and multiple sclerosis.